Compare · Head-to-head
Melanotan I vs PT-141.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with PT-141, then use the table to confirm fit.
PT-141 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | Melanotan I | PT-141 |
|---|---|---|
| Primary fit | skin & hair research where you want a clear starting point | sexual health & libido research where you want a clear starting point |
| Evidence | Tier A | Tier A |
| Risk | medium | low |
| Experience level | advanced | advanced |
| Budget tier | premium | premium |
| Administration route | subcutaneous implant | subcutaneous |
02 · Use case & timing
| Decision factor | Melanotan I | PT-141 |
|---|---|---|
| Goal fit | Skin & Hair | Sexual Health & Libido |
| What users compare it for | Phototoxicity reduction in EPP (evidence-backed). Cosmetic tanning is not the approved use. | Improved sexual desire in premenopausal women with acquired generalized HSDD. |
| Onset timeline | Controlled-release kinetics; plasma concentrations up to ~96 hours in most subjects. | Designed for acute/as-needed effect within an hour; BP effects peak in hours post-dose. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Melanotan I | PT-141 |
|---|---|---|
| Adverse effects | Hypersensitivity, implant site reactions, pigment changes, monitoring for pigmented lesions. | Nausea, flushing, injection site reactions, headache, vomiting. BP elevation. |
| Contraindications | Hypersensitivity to afamelanotide (per label). | Uncontrolled hypertension, known cardiovascular disease. Avoid co-use with oral naltrexone-containing products. |
| Interaction notes | No drug interaction studies were conducted (per label). | Slowed gastric emptying impacts absorption of concomitant oral meds. Clinically meaningful interaction with oral naltrexone. |
| Regulatory status | Prescription-approved | Prescription-approved |
| FDA flag | No current flag noted | No current flag noted |
| WADA status | Status unclear | Not listed |
04 · Age & monitoring
| Decision factor | Melanotan I | PT-141 |
|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54, 55-64 |
| Life-stage note | Not yet documented | Adult sexual-health use case with strongest fit before later-life cardiovascular burden becomes a larger concern. |
| Monitoring burden | Not specified | medium |
| Follow-up cadence | Not yet documented | Review tolerance early and reassess if use becomes frequent. |
05 · Cost & sourcing
| Decision factor | Melanotan I | PT-141 |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | €27.29 |
| Estimated monthly cost | No reliable estimate yet | €27.29 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | Melanotan I | PT-141 |
|---|---|---|
| Tracked vendor listings | 2 listings | 3 listings |
| Sourcing note | Tracked product pages are available, which makes it easier to review the listing before you click out. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Better as a standalone decision | Better as a standalone decision |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.